Clinical trials
Metastatic Colorectal Carcinoma clinical trials
Below are recruiting metastatic colorectal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 224 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06341296RecruitingPhase 2
Irinotecan liposomes for first-line advanced colorectal cancer
This trial tests a new type of chemotherapy (irinotecan liposomes) as a first treatment for metastatic colorectal cancer that has not been treated before. It focuses on patients with specific genetic changes (RAS or BRAF V600E mutation) or right-sided colon cancer, and looks at how well the drug works.
Sichuan, Sichuan, ChengduAges 18–85 - NCT06425133RecruitingPhase 2
Regorafenib plus low-dose chemo for advanced colorectal cancer
This trial tests a combination of regorafenib (a targeted pill that cuts off blood supply to tumors) with a low-dose, continuous chemotherapy regimen for people whose colorectal cancer has spread and is no longer responding to standard treatments. The goal is to see if this mix can slow or stop the cancer's growth.
AuxerreAges 18 years+ - NCT06887218RecruitingPhase 2
Testing a new combination for advanced colorectal cancer
This trial tests a combination of two drugs, regorafenib and 5-FU with leucovorin, for people with colorectal cancer that has spread and has not responded to at least two previous treatments. The goal is to see if this new mix can help shrink or control the cancer.
Houston, TexasAges 18 years+ - NCT06980532RecruitingPhase 1/Phase 2
Glumetinib and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two targeted drugs (Glumetinib and Fruquintinib) for people with a specific type of advanced colorectal cancer that has a change in the MET gene (amplification) or too much MET protein. It is for those whose cancer has not responded to at least two prior treatments.
Wuhan, HubeiAges 18 years+ - NCT07042685RecruitingPhase 2
5-FU and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
Houston, TexasAges 18 years+ - NCT07309289RecruitingPhase 3
Comparing two drug combos for first-line metastatic colorectal cancer
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than another standard combination (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer who haven't had treatment yet. It aims to find a more effective first treatment option.
ShanghaiAges 18 years+ - NCT07389265RecruitingPhase 3
Continuing cetuximab after first treatment stops working for metastatic colorectal cancer
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
AnconaAges 18 years+ - NCT07559760RecruitingPhase 2
New combination therapy for advanced colorectal cancer after first treatment
This trial tests a new drug combination for colorectal cancer that has spread to other parts of the body and did not respond to or could not tolerate standard first-line chemotherapy. The goal is to see if this new approach can help shrink the cancer and extend survival.
Changchun, JilinAges 18–75 - NCT06936527Enrolling by invitationPhase 1/Phase 2
Combination therapy for metastatic colorectal cancer with RAS mutation
This trial tests a new drug called XS-03 combined with standard chemotherapy and bevacizumab for people with metastatic colorectal cancer that has a specific genetic change called a RAS mutation. It aims to see if this combination is more effective than current treatments.
BeijingAges 18–70 - NCT07082439RecruitingPhase 2
Pembrolizumab and Odetiglucan for Liver-Dominant Colorectal Cancer
This study tests a combination of two drugs, pembrolizumab and odetiglucan, in people whose colorectal cancer has spread mainly to the liver and has not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of liver tumors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06959589Enrolling by invitationPhase 2
Combination therapy for KRAS G12C mutated colorectal cancer
This trial tests a new drug combination (IBI351, cetuximab, and FOLFIRI) as first treatment or as a second treatment after standard chemotherapy for people with KRAS G12C mutated colorectal cancer that has spread. The goal is to see if it works well and is safe.
Hangzhou, ZhejiangAges 18–75 - NCT06282445RecruitingPhase 2
Combination therapy for first-line metastatic colorectal cancer
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
Jinhua, ZhejiangAges 18–75 - NCT05759728RecruitingPhase 1/Phase 2
LGR5-targeted CAR-T for metastatic colorectal cancer
This early-phase study tests an autologous CAR-T cell treatment that is designed to recognize LGR5 on colorectal cancer cells. It aims to shrink metastatic colorectal cancer that has already been treated with up to two prior standard chemotherapy regimens.
Adelaide, South AustraliaAges 18 years+ - NCT06008119RecruitingPhase 3
Targeted pill combination for BRAF-mutated metastatic colorectal cancer
This study tests a combination of two targeted pills (tunlametinib and vemurafenib) for people with metastatic colorectal cancer that has a specific gene change (BRAF V600E) and whose cancer has grown after at least one prior treatment. The goal is to see if this drug combination can shrink tumors or slow cancer growth.
Beijing, Beijing MunicipalityAges 18–70 - NCT05991102Recruiting
Radiofrequency treatment with Lonsurf and Avastin for advanced colorectal cancer
This trial tests if adding a special radiofrequency treatment to the drugs Lonsurf (TAS-102) and Avastin (bevacizumab) can help people whose colorectal cancer has spread to the liver and has not responded to previous treatments. It is for patients with limited options who have already tried at least two standard chemotherapy regimens.
BerlinAges 18 years+ - NCT06202183Recruiting
Home exercise for gut health in young colorectal cancer patients
This study tests whether a home-based exercise program can improve the health of your gut bacteria during chemotherapy for young-onset colorectal cancer. It aims to help you feel better and potentially improve how well your treatment works.
Boston, MassachusettsAges 18–50 - NCT07321106RecruitingPhase 1
CBI-1214 for advanced colorectal cancer
This trial tests a new drug called CBI-1214, which is designed to help your immune system attack cancer cells. It is for people with advanced colorectal cancer that has not responded to other treatments.
Phoenix, ArizonaAges 18 years+ - NCT06553885RecruitingPhase 2
Study of enfortumab vedotin for advanced colorectal or liver cancer
This trial tests a drug called enfortumab vedotin for people whose colorectal or liver cancer has spread or cannot be removed and has stopped responding to or is intolerant to standard treatments. The drug is given through a vein and works by targeting cancer cells.
Tampa, FloridaAges 18 years+ - NCT06889610RecruitingPhase 2
Ablation plus drug therapy for advanced solid tumors
This trial tests combining a liver tumor ablation procedure with systemic drugs for people with advanced colorectal, breast, or melanoma cancer that has spread to the liver. The goal is to see if this approach can help when standard treatments have stopped working.
ShanghaiAges 18–80 - NCT07281716RecruitingPhase 1/Phase 2
Immunotherapy combo for advanced colorectal cancer
This trial tests a combination of immunotherapy drugs for people with a specific type of colorectal cancer (MSS, or microsatellite stable) that has stopped responding to standard chemotherapy. The goal is to see if this new treatment can shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT05963490RecruitingPhase 2
Regorafenib with or without targeted immunotherapy and radiation for spread colon cancer
This Phase 2 study tests whether taking regorafenib alone or with immunotherapy (toripalimab) and a lower-dose radiation plan can better control metastatic colon or rectal cancer that has MSS/pMMR. It may help by combining cancer-blocking medicine with immune activation and focused radiation to metastatic spots.
ShanghaiAges 18–70 - NCT05904665Recruiting
Blood methylation test to guide follow-up after colon cancer surgery
This study checks a special blood test (circulating tumor DNA methylation) to help guide follow-up after surgery for non-metastatic colon cancer. It may help find whether additional treatment or closer monitoring is needed based on the test results.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06525428RecruitingPhase 2
Adding radiation and immunotherapy to standard care for advanced colorectal cancer
This trial is testing a combination of standard chemotherapy, radiation therapy, and an immunotherapy drug (toripalimab) for people with metastatic colorectal cancer. It aims to see if adding radiation therapy and immunotherapy can help shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04912765RecruitingPhase 2
New immune vaccine plus nivolumab for liver cancer
This trial studies whether an individualized “neoantigen” cancer vaccine given to immune cells (dendritic cells) plus nivolumab can improve outcomes in people with liver cancer and/or colorectal cancer that has spread only to the liver. It focuses on tumors that can be removed with curative surgery (with or without local ablation) and on people with good enough liver and overall health.
SingaporeAges 21 years+
Hear when a new Metastatic Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic colorectal carcinoma?
- Yes. Clin2 currently lists 224 recruiting metastatic colorectal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic colorectal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic colorectal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.